VEGF is one of the most potent pro-angiogenic factors secreted by tumor cells. It binds to specific receptors on the surface of endothelial cells, leading to their proliferation, migration, and new vessel formation. Inhibitors of VEGF, such as bevacizumab, are used in cancer therapy to disrupt this angiogenic signaling pathway, thereby inhibiting tumor growth.
